VKH
MTNB icon

Virtu KCG Holdings’s Matinas BioPharma MTNB Stock Holding History

Virtu KCG Holdings’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$408K Buy
4,833
+3,443
+248% +$462K 0.01% 1342
2017
Q1 		$193K Buy
+1,390
New +$227K 0.01% 2453

Other funds holding MTNB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
AWMG
Alliance Wealth Management Group Flemington, New Jersey $457M AUM 12.13% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Virtu KCG Holdings's MTNB Position: Q2 2017 in Review

Virtu KCG Holdings increased its Matinas BioPharma (MTNB) stake by 248% in Q2 2017, buying an estimated $462K and bringing the position to 4,833 shares worth $408K. The position accounts for 0.01% of the portfolio, ranked #1342.

Virtu KCG Holdings first reported a position in MTNB in Q1 2017 and has held it in 2 quarters since. 45 funds tracked by Wall St. Rank hold MTNB as of Q2 2017.

  • Virtu KCG Holdings held 4,833 shares of Matinas BioPharma worth $408K as of Q2 2017.
  • Virtu KCG Holdings bought 3,443 Matinas BioPharma shares in Q2 2017, an estimated $462K.
  • Matinas BioPharma made up 0.01% of Virtu KCG Holdings's portfolio in Q2 2017, its #1342 holding.
  • Virtu KCG Holdings first reported a position in Matinas BioPharma in Q1 2017 and has held it in 2 quarters since.
  • 45 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.